To Whom it May Concern:

In response to inquiries, the Health Resources and Services Administration (HRSA) reviewed its policies regarding rebates to AIDS Drug Assistance Programs (ADAPs) under the 340B Drug Pricing Program. As a result of this review, HRSA plans to propose a rule that will address the extent to which ADAPs can collect rebates from manufacturers when the ADAPs purchase insurance and/or pay premiums, copayments, and deductibles for ADAP patients.

The rule will be subject to public notice and comment prior to implementation. In the meantime, HRSA urges manufacturers to continue their current ADAP rebate operations in order to maintain stability in the ADAP program.

Sincerely,

Mary K. Wakefield, Ph.D., R.N.
Administrator